---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-228289"
form_type: "8-K"
ticker: "FDMT"
cik: "0001650648"
company_name: "4D Molecular Therapeutics, Inc."
filed_at: "2025-10-02T23:59:59+00:00"
generated_at: "2026-05-17T04:56:11.043553+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# 4D Molecular Therapeutics appoints Ashoo Gupta as Principal Financial Officer

## Summary
- Ashoo Gupta appointed Principal Financial Officer and Principal Accounting Officer effective September 30, 2025.
- Mr. Gupta previously served as VP Finance & Controller at 4D since June 2024.
- Prior roles include VP Finance and Corporate Controller at Kyverna Therapeutics and Executive Director of Accounting at Myovant Sciences.
- Board amended and restated bylaws to update advance notice procedures for business and director nominations.

## SEC filing metadata
- accession: 0001193125-25-228289
- form_type: 8-K
- ticker: FDMT
- cik: 0001650648
- company_name: 4D Molecular Therapeutics, Inc.
- filed_at: 2025-10-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650648/000119312525228289/0001193125-25-228289-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650648/000119312525228289/fdmt-20250930.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-228289
- JSON: https://secwatch.observer/filing/0001193125-25-228289.json
- Plain text: https://secwatch.observer/filing/0001193125-25-228289.txt

## Key facts
- Governance Changes
  4D Molecular Therapeutics, Inc.: Board amended and restated Bylaws to update advance notice procedures for business brought before a meeting and for nominations of directors (effective 2025-09-30).
  - Change: bylaw amendment
  - Effective: 2025-09-30
  source text: On September 30, 2025, the Board amended and restated the Company’s current amended and restated bylaws (the “Amended and Restated Bylaws”). The Amended and Restated Bylaws were amended to, among other revisions, update the advance notice procedures for business brought before a meeting and update the advance notice procedures for nominations of directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1650648/000119312525228289/0001193125-25-228289-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.